Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
about
Warfarin pharmacogenetics: does more accurate dosing benefit patients?The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics StudyMultiplex detection and SNP genotyping in a single fluorescence channelValidation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingComparative performance of gene-based warfarin dosing algorithms in a multiethnic population.Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisCardiovascular pharmacogenomicsEnzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery.Clinical application of high throughput molecular screening techniques for pharmacogenomics.Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patientsRole of pharmacogenomics in the management of traditional and novel oral anticoagulantsImplementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.Improving oncology outcomes through targeted therapeutics will require electronic delivery systems.Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis.Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study.Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivityCombined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.Warfarin genotyping using three different platforms.Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort.A randomized controlled trial of genotype-based Coumadin initiation.Establishment of a CYP2C19 genotyping assay for clinical use.Pharmacogenomics Aspect of Warfarin TherapyPharmacogenomics, ancestry and clinical decision making for global populations
P2860
Q27027304-BC2C1ABD-FD55-4F95-A672-B4A59EF91751Q28553937-904C02CF-FDA1-4688-ACFF-ED02C8A1295DQ28732753-5CB18746-56E3-4AFF-92B6-9EA13110597DQ33813830-D51366D4-721B-44C3-9A1B-BF6F81006E4CQ34096562-E8DE4DE0-9FEF-45A6-9141-F7A98F738960Q34234122-080B0AB5-A066-4F35-8911-6AD53AE801BFQ35185164-1EB68201-7373-44E9-84C9-EC1B284EDE36Q35447163-1F553B31-43C2-4F6F-944B-D3902156E494Q36118277-BE35B8AF-C75E-4942-BF97-D3B6800B7A20Q36441517-DC51886A-50B9-47E5-850D-FB9406CB03E0Q36511894-6E7EF0EB-82FD-4216-A02A-7B59FEDE5532Q36848449-D9378486-721B-4186-9A78-19CFDA10F2E5Q37433329-672038DA-AE6D-47F3-89A2-A646B047BB4DQ37875079-1F7318A8-4235-49CA-BCD9-D95EC4B3DB6FQ38979667-5DF335FC-2F53-4A2D-9ADE-CEF720F93D11Q39862947-6DD2B721-ECD3-41D5-98A5-5841B90F3AFFQ42130578-4BBDE874-E4A2-45BC-971D-3F16936E0043Q42182060-EADDB6E4-5FBB-4F86-AF9D-37EDFC93E41EQ42253522-AAC68EC5-1700-432E-AA8A-ABB82995F821Q42531773-EA47BB61-2656-496B-A7DB-2430B082AC5DQ42722363-A51BB97D-E2E7-41F6-B00D-E34B35CAE704Q42750392-187E8928-E849-40DE-B546-968F351E016CQ46133587-DDFE9464-CC68-42F1-8BF1-C4A4FFA1837FQ51588530-CA7FA3E7-86F0-4EF1-9721-EFE33D5030F2Q54274143-EAB19492-DD5A-496F-AB53-7CDA75EEE793Q57179825-386837FE-7527-43B4-B8C9-EDC2912537EEQ57278395-DE4F768F-3D75-445F-8AE7-373881629AB7
P2860
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@en
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@nl
type
label
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@en
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@nl
prefLabel
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@en
Validation of clinical testing ...... nd warfarin-dosing algorithms.
@nl
P2093
P2860
P1476
Validation of clinical testing ...... and warfarin-dosing algorithms
@en
P2093
Howard L McLeod
James P Evans
Jessica K Booker
Michael R Langley
P2860
P304
P356
10.2353/JMOLDX.2009.080123
P50
P577
2009-03-26T00:00:00Z